Clinical Trial Update: To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 study update evaluating the relative bioavailability of Bupropion HCl extended-release 300 mg tablets under fasting conditions (Sandoz).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Bupropion HCl Extended-Release 300 mg tablets (bupropion hydrochloride extended-release 300 mg)

Snippet

Sponsor: Sandoz | Conditions: Depression | Phase 1 | Status: COMPLETED